DFX Intelligence
Private Equity Intelligence
Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Transactions / S••
A••••••• L••• S•••••• T•••• • S••••••• acquires IRAB, a leading independent radiopharmaceuticals platform
Platform acquisitionannouncedannounced Jun 9, 2026Fact
What happened
- Target
- S••
- Platform
- not an add-on on record
- Control
- Control
- Share acquired
- unknown
- Industry
- healthcare / pharma
- Target location
- unknown
- Seller kind
- unknown
- Rollover
- unknown
Values, only where disclosed
- Enterprise value
- Not disclosed
- Purchase price
- Not disclosed
- Equity value
- Not disclosed
- Target revenue
- Not disclosed
- Target EBITDA
- Not disclosed
- Multiple
- Not disclosed
Parties and roles
4 named
Buy side
- ““IRAB has built a distinctive position at the intersection of radiopharmaceutical manufacturing, innovation and clinical service excellence,” says R•••• F•••••••••, Partner at A•••••••.”
- “With offices in Europe, North America and Asia, A••••••• is a leading investment firm focused exclusively on healthcare industries.”
Side not stated
- ““This is an important milestone for IRAB and for the partners we serve,” says J••• T••••, CEO of IRAB.”
- “A••••••• L••• S•••••• T•••• • S••••••• acquires IRAB, a leading independent radiopharmaceuticals platform”
Evidence
“A••••••• L••• S•••••• T•••• • S••••••• acquires IRAB, a leading independent radiopharmaceuticals platform”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026